VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“ Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate…

Source

Previous articleMany Trips, Diminishing Returns: Cross-Tolerance Between LSD and DOI
Next articleRevive Therapeutics Ltd. Announces Offering of Up to $5 Million